Clinical pharmacology of fentanyl buccal tablet for the treatment of breakthrough pain

References

• Portenoy RK, Hagen NA. Breakthrough pain: definition and management. Oncology (Williston Park, NY)3(8 Suppl.), 25–29 (1989).
   PubMedGoogle Scholar
• Svendsen KB, Andersen S, Arnason S et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur. J. Pain9(2), 195–206 (2005).
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Caraceni A et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer94(3), 832–839 (2002).
   PubMed Web of Science ®Google Scholar
• Caraceni A, Martini C, Zecca E et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat. Med.18(3), 177–183 (2004).
   PubMed Web of Science ®Google Scholar
• Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J. Pain Symptom Manage.20(2), 87–92 (2000).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Bennett DS, Rauck R et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J. Pain7(8), 583–591 (2006).
   PubMed Web of Science ®Google Scholar
• Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat. Med.15(3), 243–246 (2001).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain41(3), 273–281 (1990).
   PubMed Web of Science ®Google Scholar
• Bennett DS, Burton AW, Fishman S et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1. Pharmacol. Ther.30, 296–301 (2005).
   Google Scholar
• Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain81(1–2), 129–134 (1999).
   PubMed Web of Science ®Google Scholar
• Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain101(1–2), 55–64 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor DR, Webster LR, Chun SY et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med.8(3), 281–288 (2007).
   PubMed Web of Science ®Google Scholar
• Bennett DS, Burton AW, Fishman S et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2. Pharmacol. Ther.30, 354–361 (2005).
   Google Scholar
• Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst. Rev.CD004311 (2007).
   Google Scholar
• Stanley TH. Fentanyl. J. Pain Symptom Manage.29, S67–S71 (2005).
   PubMed Web of Science ®Google Scholar
• Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat. Med.14(1), 57–58 (2000).
   PubMed Web of Science ®Google Scholar
• Darwish M, Tempero K, Kirby M, Thompson J. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin. Pharmacokinet.44(12), 1279–1286 (2005).
   PubMed Web of Science ®Google Scholar
• Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets. Am. J. Drug Deliv.4, 1–5 (2006).
   Google Scholar
• Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin. J. Pain22(9), 805–811 (2006).
   PubMed Web of Science ®Google Scholar
• McCurdy CR. Development of opioid receptor ligands. In: Analogue-Based Drug Discovery. Fischer J, Ganellin CR (Eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany 259–258 (2006).
   Google Scholar
• Inturrisi CE. Clinical pharmacology of opioids for pain. Clin. J. Pain18(4 Suppl.), S3–S13 (2002).
   PubMedGoogle Scholar
• Taylor DR. The pharmacology of fentanyl and its impact on the management of pain. Med. Neurol. Neuro.7 (2005).
   Google Scholar
• Eichman JD, Robinson JR. Mechanistic studies on effervescent-induced permeability enhancement. Pharm. Res.15(6), 925–930 (1998).
   PubMed Web of Science ®Google Scholar
• Pather SI, Siebert JM, Hontz J, Khankari RK, Gupte SV, Kumbale R. Enhanced buccal delivery of fentanyl using the oravescent drug delivery system. Drug Deliv. Technol.1, 54–57 (2001).
   Google Scholar
• Mather LE, Gourlay GK. Pharmacokinetics of fentanyl. In: Transdermal Fentanyl.. Lehman KA, Zech D (Eds). Springer-Verlag, Heidelberg, Germany 73–97 (1991).
   Google Scholar
• Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a Phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin. Ther.28(5), 707–714 (2006).
   PubMed Web of Science ®Google Scholar
• Darwish M, Tempero K, Kirby M, Thompson J. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 pg versus oral transmucosal fentanyl citrate 1600 pg and dose proportionality of FEBT 270 to 1300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin. Ther.28(5), 715–724 (2006).
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J. Clin. Pharmacol.47(3), 343–350 (2007).
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P Jr, Hellriegel E, Jiang JG. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J. Clin. Pharmacol.47(1), 56–63 (2007).
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P Jr, Hellriegel E, Jiang JG. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin. Pharmacokinet.45(8), 843–850 (2006).
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Jiang JG. Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin. Pharmacother.8(13), 2011–2016 (2007).
   PubMed Web of Science ®Google Scholar
• Palkama VJ, Neuvonen PJ, Olkkola KT. The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl. Br. J. Anaesth.81(4), 598–600 (1998).
   PubMed Web of Science ®Google Scholar
• Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir’s role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology91(3), 681–685 (1999).
   PubMed Web of Science ®Google Scholar
• Cheng KK. Oral mucositis, dysfunction, and distress in patients undergoing cancer therapy. J. Clin. Nurs. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Kin-Fong CK. Oral mucositis and quality of life of Hong Kong Chinese patients with cancer therapy. Eur. J. Oncol. Nurs.11(1), 36–42 (2007).
   PubMedGoogle Scholar
• Stone R, Fliedner MC, Smiet AC. Management of oral mucositis in patients with cancer. Eur. J. Oncol. Nurs.9(Suppl. 1), S24–S32 (2005).
   Google Scholar
• Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin. Drug Investig.27(9), 605–611 (2007).
   PubMed Web of Science ®Google Scholar
• Hug CC Jr, Murphy MR. Tissue redistribution of fentanyl and termination of its effects in rats. Anesthesiology55(4), 369–375 (1981).
   PubMed Web of Science ®Google Scholar
• Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin. Pharmacokinet.8(5), 422–446 (1983).
   PubMed Web of Science ®Google Scholar
• Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth. Intensive Care33(3), 311–322 (2005).
   PubMedGoogle Scholar
• Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J. Support. Oncol.5(7), 327–334 (2007)
   PubMedGoogle Scholar
• Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J. Pain Symptom Manage.25(5), 406–411 (2003).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr. Med. Res. Opin.23(1), 223–233 (2007).
   PubMed Web of Science ®Google Scholar
• Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther.29, 588–601 (2007).
   PubMed Web of Science ®Google Scholar